Monthly Archives: May 2016

Morning Technical Review on Medical Appliances and Equipment Stocks

LONDON, UK / ACCESSWIRE / May 26, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Boston Scientific, Abbott, Medtronic, and Hologic.

Today, ActiveWallSt.com is promoting its technical alert briefings. Get all of our alerts free by signing up to http://www.activewallst.com/.

The Medical Appliances and Equipment industry continues to impress with several companies. This morning, let us see how the current market conditions are affecting some of the big names in the industry. Sign up and register for your free technical alerts on these stocks by clicking on the following link:

http://www.activewallst.com/

Let us take a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions.

Boston Scientific Corp. (NYSE: BSX)

On Wednesday, shares in global medical devices maker, Boston Scientific Corp., recorded a trading volume of 8.63 million shares. The stock ended the day at $22.39, which was a slight correction of 0.62%. The Company’s shares have gained 13.71% in the last one month, 29.27% over the previous three months, and 21.42% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.68% and 23.32%, respectively. Furthermore, shares of Boston Scientific have a Relative Strength Index (RSI) of 68.24. Back in April 28th, 2016, research firms Barclays, RBC Capital Markets, Stifel, and Wedbush reiterated their previous ratings on the Company’s stock, which were ‘Overweight’, ‘Outperform’, ‘Buy’ and ‘Neutral’, respectively.

Abbott Laboratories (NYSE: ABT)

International health care products manufacturer, Abbott Laboratories’ stock finished yesterday’s session 1.84% higher at $38.68. A total volume of 16.14 million shares was traded, which was above their three months average volume of 8.65 million shares. The Company’s shares are trading below their 50-day moving average by 4.81%. Furthermore, shares of Abbott have an RSI of 46.81.

Medtronic PLC (NYSE: MDT)

At the closing bell on Wednesday, shares in device-based medical therapies manufacturer, Medtronic PLC, gained 0.17%, ending the day at $81.08. The stock recorded a trading volume of 4.48 million shares. The Company’s shares have advanced 3.00% in the last one month, 4.93% in the previous three months, and 5.94% on an YTD basis. The stock is trading 4.00% above its 50-day moving average and 8.14% above its 200-day moving average. Moreover, shares of Medtronic have an RSI of 60.17.

Hologic Inc. (NASDAQ: HOLX)

Massachusetts-based Hologic Inc. is a developer, manufacturer, and supplier of women’s diagnostics products, medical imaging systems, and surgical products. The Company’s stock ended the day 0.48% higher at $33.61 and with a total volume of 3.53 million shares traded. The Company’s shares are trading 3.58% below their 50-day moving average. The stock has an RSI of 43.73. Back in April 28th, 2016, research firm Needham downgraded the Company’s stock rating from ‘Buy’ to ‘Hold’. Get free access to your trade alert on HOLX at:

http://www.activewallst.com/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.activewallst.com.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: ActiveWallSt.com

ReleaseID: 440436

Zecotek Increases Non-Brokered Private Placement to $925,000 and Closes First Tranche of $678,000

SINGAPORE / ACCESSWIRE / May 26, 2016 / Zecotek Photonics Inc. (TSXV: ZMS) (FSE: W1I) (the “Company”), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company has increased the non-brokered private placement announced on May 19, 2016 to $925,000. The Company also announced it has closed on the first tranche of the private placement by selling 2,259,997 units of the Company at a price of $0.30 per unit for gross proceeds of $678,000.

Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of $0.43 per common share until May 26, 2018.

The Company paid finder’s fees on the first tranche consisting of cash fees totalling $47,459.94 and issued 158,200 finder’s warrants. Each finder’s warrant entitles the holder to acquire one common share at an exercise price of $0.43 per common share until May 26, 2018.

All securities issued in the first tranche are subject to a four-month hold period expiring on September 27, 2016.

Net proceeds from the funds raised will be used to complete the transfer of technology for the purpose of immediate commercialization, to strengthen and maintain patents of the Company’s IP portfolio, for purchase order financings and general working capital purposes.

About Zecotek

Zecotek Photonics Inc (TSXV: ZMS) (FSE: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors.  Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

SOURCE: Zecotek Photonics Inc.

ReleaseID: 440443

Big Sky Petroleum Transfers to NEX

VANCOUVER, BC / ACCESSWIRE / May 26, 2016 / Big Sky Petroleum Corporation (TSXV: BSP) (OTC: BGKYF) (“Big Sky” or the “Company“) is advising that, in accordance with TSX Venture Exchange Policy 2.5, the Company has not maintained the requirements for a Tier 2 Company.Effective as of market opened on Thursday, May 26, 2016, the Company’s listing was transferred to the NEX Board (“NEX”) of the TSX Venture Exchange (the “TSXV”), the Company’s Tier classification changed from Tier 2 to NEX, and the Filing and Service Office changed from Vancouver to NEX.

The trading symbol for the Company was changed from BSP to BSP.H. There is no change in the Company’s name, no change in its CUSIP number and no consolidation of capital.The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSXV. As of May 26, 2016, the Company is also subject to restrictions on share issuances and certain types of payments as set out in the NEX policies.

NEX is a separate board of the TSXV for companies previously listed on TSXV or Toronto Stock Exchange which have failed to maintain compliance with the ongoing financial listing standards of those markets. NEX has been designed to provide a forum for the trading of publicly listed shell companies while they seek and undertake transactions in furtherance of their reactivation as companies which will carry on an active business.

“Mark T. Brown”
President and Chief Executive Officer

For additional information, contact Sandrine Lam at 604-687-3520 Extension 250 (sandrine@pacificopportunity.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Big Sky Petroleum Corporation

ReleaseID: 440442

SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO), Raises Price Target to $1.75

NEW YORK, NY / ACCESSWIRE / May 26, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).

“Importantly, PBIO’s growth came from its core products and services segment, which we see as offering insight on the pace at which the company is gaining traction in the market. This is particularly true considering its recent co-marketing agreement with SCIEX, a global leader in mass spectrometry and scientific lab analysis, and a wholly-owned subsidiary of Danaher Corporation – a $60bn holding company, which has not even factored into PBI’s revenue growth as of yet. We believe this represents tremendous unrealized value for PBIO,” stated Ajay Tandon, CEO of SeeThruEquity. “Based on the results over the past year and expectations for the near future, we are increasing our price target to $1.75 per share.”

The report is available here: PBIO May 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on all of these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the update note are as follows:

Strong opening to 2016 at PBIO

PBIO has had an impressive start to 2016, continuing momentum from 2015, when the company grew total revenues by 30% over 2014. PBIO reported 16% YoY top line growth in 1Q16 (described in more detail below), supported by 26% growth in its Products and Services segment, which we see as the key to long term growth and expanding margins for the company. We are hopeful this momentum will continue given the recent new strategic relationship with mass spectrometry leader SCIEX. Additionally, PBIO management continues to execute on the corporate development front, raising $1.4mn of fixed-rate convertible debt during the quarter from its now completed PIPE offering. In a recent investor call, the company also reiterated its plans to up-list to a national exchange, such as the NASDAQ and/or NYSE.

Robust growth in products in 1Q16

PBIO began 2016 with a strong start, with 1Q16 revenues climbing 16% YoY to reach $454,350. Most impressively, the company grew revenues in its Products & Services segment by 26.4%. Although we expect the company to continue to generate high margin grant revenues (which management expects to bounce back later this year), clearly the key to the investment thesis for PBIO is a growing adoption of its instruments and consumables in the market – and 26.4% growth is impressive progress in this area. The quarter was highlighted by a 41% rise in new instrument sales, which should drive future consumable sales, which have recurring-like attributes with high incremental margins, as the instruments are adopted by PBIO customers.

Looking for continued growth in 2016 over 2015

Although PBIO did not provide specific guidance in its 1Q16 release, management did state that the company is striving for “rapid and dramatic growth in the near future.” Considering this statement, as well as the recently announced co-marketing agreement with mass spectrometry leader SCIEX, we have increased confidence in PBIO’s ability to execute its growth plan. We are expecting continued healthy double-digit growth in products and services throughout 2016E, and are eager to learn more about the extent to which the SCIEX arrangement can layer incremental growth on top of PBIO’s own sales efforts. We note that SCIEX is a global leader in mass spectrometry and scientific lab analysis, and a wholly-owned subsidiary of Danaher Corporation – a $60bn holding company. We see the deal as supporting PBIO’s claims for the potential of its PCT product line, as well as an expedient means to accelerate growth given the much more extensive sales distribution at SCIEX, which we expect to see manifested in the quarters to come.

Increasing target to $1.75 for PBIO

Nice 1Q16 top line growth and improving performance in the company’s products and services business has increased our confidence in PBIO’s ability to execute its growth strategy. Considering this, as well as the evident progress made by the company in attracting industry leading partners, such as SCIEX, we are increasing our price target $1.75 for the company.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 440440

XFit Brands, Inc. to Present at the LD Micro Invitational

LOS ANGELES, CA / ACCESSWIRE / May 26, 2016 / XFit Brands, Inc. (OTCQB: XFTB), a global supplier of fitness and MMA equipment sold at retail and fitness outlets worldwide whose brands include XFit Brands®, Throwdown®, and Transformations™, today announced that it will be presenting at the 6th annual LD Micro Invitational on Tuesday June 7th at 4:00 PM PST / 7:00 PM EST. David Vautrin, Chief Executive Officer of XFit Brands will be giving the presentation and meeting with investors.

Xfit Brands has been taking advantage of the global growth in health and wellness. The underlying industry has been growing at more than 5% compound annually, as the trends to healthier lifestyles and away from obesity take hold worldwide. Fitness outlets and major gym chains are rapidly expanding around the world, and XFit is capitalizing on this by being a one-stop-shop supplier to them. Historically gyms focused on stationary equipment like treadmills and weight machines. The trend is towards active cross and group training – and this is the type of functional fitness equipment and programming that XFit® provides. As a result, the fitness outlets drive new sources of revenue and engage with their customer bases to increase retention and loyalty. Xfit Brands®, Throwdown® in impact sports and accessories and Transformations® in programming and training is at the heart of this movement, and is why the company is growing more than 40% annually.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small / micro-cap space.

View XFit, Brands profile here: http://www.ldmicro.com/profile/XFTB

Profiles powered by LD Micro News Compliments of Accesswire

About XFit Brands®

XFit Brands, Inc. is one of the leading suppliers of functional fitness brands, products, and equipment sold at retail and fitness outlets worldwide. The company provides a full portfolio of products and services spanning MMA, Cross Training, and other High and low impact fitness regimes and owns the trademarks XFIT® for its Functional Fitness line, Throwdown® for its MMA portfolio, and Transformations® in programming. The company’s portfolio of brands and products are sold throughout the world and they supply many of the leading Health Club organizations throughout the United States. The Company’s websites are www.xfitbrands.com and www.throwdown.com. Follow us on Facebook, Throwdown Industries and XFit Brands.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: David E. Vautrin
Phone: 949-916-9680
Address: 25731 Commercentre Drive, Lake Forest, CA 92630
Email: InvestorRelations@XFitBrands.com

SOURCE: XFit Brands, Inc. via LD Micro

ReleaseID: 440394

MMHC Acquisition Creates Advantage In Retail Market

Medically Minded Initial Sales Test Marketing of Recently Acquired Inventory Estimates Retail Value in Excess of $150,000

WEST PALM BEACH, FL / ACCESSWIRE / May 26, 2016 / Medically Minded, Inc. (OTC PINK: MMHC), announced today that it has completed various sales test marketing of the products recently acquired and delivered from Health Synergy, Inc. The test marketing involved the pricing of the products under tiered pricing structures to determine the most favorable price point for each item. The Company, based on these test efforts, has experienced daily revenues and established what it believes to be the optimal pricing points to generate the most sales.

The Company’s initial inventory of products include CBD Vape Oil in 3 Flavors (Strawberry Kiwi, Rainbow Cream and Menthol) of 50mg or 150mg, CBD Honey Stix 3 -Pack, Pharma Grade CBD Energy Powder, CBD Infused Shampoo, CBD Infused Conditioner and CBD Infused Body Lotion. The Company has placed an estimated retail value in excess of $150,000 on this inventory based on the number of units of each product on hand along with the recently established pricing structures. The inventory does not include the Company’s recently announced launch of a Medically Minded brand of 0.5 ounce and 1-ounce Hemp Oil Tinctures, which the Company expects to take initial delivery of over the next couple of weeks.

James Grady, CEO of Medically Minded, stated, “The true value I see in our recently tested pricing structures is that we have acquired over 100 customers in a matter of weeks and established that we have a significant enough value of inventory to fund the Company’s continued product acquisition and marketing in the short term.” Grady continued, “By achieving our estimated value of the current inventory we will be generating internal funding that is not dependent on outside financing.”

Medically Minded’s current offering and pricing of inventoried product available at www.medmindedlabs.com is:

 

Additionally, in honor of Memorial Day, the Company is offering a discount of 25% OFF all purchases at the Company’s website (www.medmindedlabs.com) by using the code THANKYOU at checkout.

About Cannabidiol (“CBD”) Oil

CBD Rich Hemp Oil is an oil extracted from Industrial Hemp plants (stalks and seeds) with a High Grade of Cannabidiol (CBD). The plants used are specifically and uniquely bred to comprise high concentrations of the naturally occurring Cannabinoid Cannabidiol (CBD). Cannabidiol oil that comes from industrial hemp plants, such as will be the case with our products, are considered by the FDA to be a dietary supplement (not a medication) since they are made from industrial hemp plants.

If you live in the US, this means you don’t need a prescription and can legally purchase and consume Cannabidiol in any state. Cannabidiol from industrial hemp also has the added benefit of having virtually no THC. This is why it’s not possible to get “high” with these products. There simply isn’t enough THC.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.

SAFE HARBOR AND INFORMATIONAL STATEMENT

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of fact, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may”, “would”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The Company is not eligible to rely on the safe harbor provided by Section 21E(c) of the Exchange Act because it is not subject to filing periodic reports under Sections 13 or 15(d) of the Exchange Act.

Contact:

James Grady, CEO
(954) 210-8063
Info@medmindedlabs.com
Twitter: https://twitter.com/medmindedlabs
Ebay: http://www.ebay.com/usr/medicallyminded
Pinterest: https://www.pinterest.com/medicallymi0603/
https://www.facebook.com/MedicallyMinded/

SOURCE: Medically Minded, Inc.

ReleaseID: 440421

Marathon Patent Group to Present at the LD Micro Invitational

LOS ANGELES, CA / ACCESSWIRE / May 26, 2016 / Marathon Patent Group, Inc. (NASDAQ: MARA) (“Marathon”), a patent licensing and commercialization company, announced today that it will be presenting at the 6th annual LD Micro Invitational on Wednesday, June 8 at 10 AM PST / 1 PM EST. Doug Croxall, Marathon’s Chief Executive Officer, will be giving the presentation and meeting with investors.

The presentation will be webcast and will be available here: http://wsw.com/webcast/ldmicro10/mara

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small / micro-cap space.

View Marathon Patent Group’s profile here: http://www.ldmicro.com/profile/MARA

Profiles powered by LD Micro – News Compliments of Accesswire

About Marathon Patent Group

Marathon is a patent licensing and commercialization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon’s strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. The Company’s commercialization division is focused on the full commercialization lifecycle which includes discovering opportunities, performing due diligence, providing capital, managing development, protecting and developing IP, assisting in execution of the business plan, and realizing shareholder value. To learn more about Marathon Patent Group, visit www.marathonpg.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Marathon Patent Group
Jason Assad
678-570-6791
Jason@marathonpg.com

SOURCE: Marathon Patent Group via LD Micro

ReleaseID: 440420

Pivot Pharmaceuticals To Present at the 5th Annual SeeThruEquity Microcap Investor Conference in New York City on May 31, 2016

BOSTON, MA and VANCOUVER, BC / ACCESSWIRE / May 26, 2016 / Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) (“Pivot” or the “Company”), an emerging biotechnology company engaged in the development of therapeutics to address unmet medical needs in women’s health, today announced that the company will present at the 5th Annual SeeThruEquity Microcap Investor Conference at Convene on 730 Third Avenue in New York City on May 31, 2016. Please click here for a list of presenting companies.

Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and company management will also be available for one-on-one meetings with institutional investors.

Conference registration: complimentary for qualified investors and equity research analysts.
In order to register as an attendee of the conference, please click HERE.

About SeeThruEquity

Since the company’s founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and undercovered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 190 names.

STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm’s research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over 1,700 1-on-1 meetings.

For more information please visit www.steconference.com.

About Pivot Pharmaceuticals, Inc.

Pivot is an emerging pharmaceutical company engaged in the development of novel therapies to address unmet medical needs in women’s health including oncology and urology. The Company has a strategic emphasis on innovative drugs that will provide new treatment options for women’s cancers as well as for unmet gynecological and urological problems. Pivot has a portfolio of novel anticancer candidates for the treatment of gynecological and breast cancers and it is also developing novel treatments to address disturbances such as lower urinary tract symptoms (LUTS). The Company has a global drug development platform that combines the strengths of the United States, Canada and India which allows accelerated drug development strategies to provide novel therapeutic options to address unmet medical needs in women’s health.

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact:

PCG Advisory Group
www.pcgadvisory.com
Sean Leous, Chief Communications Officer
(646) 863-8998

SOURCE: Pivot Pharmaceuticals, Inc.

ReleaseID: 440369

Be Active Holdings to Present at Upcoming Investor Conferences in June 2016

Marcum MicroCap Conference in New York City on June 1st; LD Micro Invitational in Los Angeles, CA on June 8th

NEW YORK, NY / ACCESSWIRE / May 26, 2016 / Be Active Holdings, Inc. (OTC: JALA), a manufacturer and marketer of Greek frozen yogurt under the Jala brand, today announced its President, Joseph Rienzi, and its Founder, Sam Pugliese, will be presenting at two upcoming investor conferences that focus on micro cap public companies. Be Active Holdings management will discuss the Company’s products, recent business highlights, strategic vision and near-term opportunities. To find Jala products near you, please visit: http://jalabars.com/find-us/.

In addition to the presentations, management will also be available for one-on-one meetings. To arrange a one-on-one meeting with management, please contact Hayden IR at hart@haydenir.com or 917-658-7878.

Event: Marcum MicroCap Conference
Location: Grand Hyatt New York
Date: Wednesday, June 1st
Time: 11:30 AM ET
http://www.marcumllp.com/microcap

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than $500 million in market capitalization. Please contact Marcum to schedule a meeting.

Event: LD Micro Invitational
Location: Luxe Sunset Bel Air
Date: Wednesday, June 8th
Time: 10:00 AM PT
http://www.events.ldmicro.com

The LD Micro Invitational is a three-day conference welcoming more than two hundred companies that have quickly become one of the most influential venues in the micro cap world today.

About Be Active Holdings, Inc.

Be Active Holdings, Inc. is a manufacturer and marketer of Greek frozen yogurt under the Jala brand. The Company manufactures and sells low fat, low calorie, all natural probiotic enriched Greek frozen yogurt under the trade name Jala. Its Greek frozen yogurt is packaged as low fat bars and pints, which are designed to appeal both the health conscious and weight conscious consumer. The Company produces high quality, low fat, low calorie, all natural novelty frozen yogurt and ice cream products. Its proprietary Greek frozen yogurt is all fat-free and is a result of its proprietary recipe and the quality of the ingredients in the mix. For more information, check out: http://jalabars.com.

Forward-Looking Statements

Forward-Looking Statements. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information

Hayden IR
hart@haydenir.com
917-658-7878

SOURCE: Be Active Holdings, Inc.

ReleaseID: 440393

Notis Global Issues Letter to Shareholders

LOS ANGELES, CA / ACCESSWIRE / May 26, 2016 / Notis Global, Inc. (OTCQB: NGBL), a pioneer in the worldwide hemp and CBD oil (cannabidiol) industry specializing in cultivation, production and consulting today issued a formal letter to its Shareholders from Jeffrey Goh, the President and Chief Executive Officer of the Company.

Dear Shareholder,

Notis Global is at a pivotal point as we navigate the worldwide hemp and CBD oil industry. As we seek to make positive strides towards becoming the industry leader, it is important to know where we came from, where we are, and where we are going. As the recently named permanent President and Chief Executive officer of Notis Global, it is vital for me to discuss this so you will understand Notis Global’s plans for future growth and creation of shareholder value over the long term in this rapidly developing market.

It is imperative to know that Notis Global has a new business model that differs vastly from the prior company. Our goal is to grow our business by generating revenues from hemp cultivation and production, including CBD oil and compounds, along with medicinal strains and potential cures – health through hemp. We believe the primary value in cannabidiol lies in legal applications in medicine supplements and cosmetics, along with edible and drink-based solutions that enhance the lives of consumers. Notis Global aims to effectively market healthy hemp oil as the basis for many beneficial products, which will be accepted in mainstream commerce, and for this company to emerge as a trusted leader within the hemp oil product industry.

The New Notis Global Team

The foundation of our success is rooted in our team and each member plays an extremely important role. As you learn what the new team has to offer, you will see how they differ from the previous management team, how they impact Notis Global’s current strategy, and how they prepare the Company for long-term success.

Prior to joining the Company in August 2014, I worked as an executive for more than 30 years in the consumer packaged goods industry for Fortune 500 companies such as Frito Lay (PepsiCo) and Procter & Gamble, both nationally and internationally. My work at Frito Lay has prepared me to take on this role at Notis Global by providing me with extensive experience in agriculture, consumer packaged goods, food safety and branding. I truly believe that the CBD and the hemp oil industry shows great promise and significant opportunity for our Company and shareholders.

Clint Pyatt, our Chief Operating Officer and Senior Vice President is one of our valued team members I would like to highlight. He is responsible for all real estate, cultivation, extraction and ancillary services which are substantial. It is his leadership and intense efforts over the past several months that enabled us to produce some of the results we can point to today. Clint is a “hands on guy” and is not afraid to get mud on his boots to make sure the grow houses, farming and production operations and all are facilities are running smoothly.

Clint also manages government affairs, a significant and growing responsibility on the local, state and national level. Clint comes to our team with real world knowledge and experience as the former CEO of CorGreen Technologies, Inc., a publicly traded, grow and retail solutions provider of products and services to licensed medical marijuana and recreational operators. His experience in the finance and real estate sectors have helped Notis Global through our early growth Clint was a member of the U.S. Marine Corps, and has served in Desert Shield, Desert Storm, and Somalia rescue efforts.

We are proud to highlight Clint as a vital member of our team. To learn more about our management team, I urge you to visit our website and read their complete bios.

In addition to our dedicated management team, we have a strong, experienced board of directors that provide us with public company knowledge, operational experience coupled with commercial know how, governmental, regulatory and compliance experience and international outreach. Their complete biographies are on our website http://www.notisglobal.com/team as well, but let me briefly introduce them to you:

Ambassador Ned L. Siegel (Ret.) joined our Board in April 2014 and was appointed Chairman on December 17, 2014. In 1997, Ambassador Siegel founded and has served as president of The Siegel Group, Inc., an international business management advisory firm, specializing in real estate, energy, utilities, infrastructure, financial services, oil & gas and cyber & secure technology. His firm has an unprecedented track record of acquiring and developing very successful master plan residential communities, corporate office / industrial parks and retail centers.

His entrepreneurial experience and government service includes appointment by Florida Governor Jeb Bush to serve as a Member of the Board of Directors of Enterprise Florida, Inc. (EFI). He was also appointed by President George W. Bush to serve as a Member of the Board of Directors of the Overseas Private Investment Corporation (OPIC), and to serve with Ambassador John R. Bolton at the United Nations in New York as a Senior Advisor to the U.S. Mission and Representative of the United States to the United Nations General Assembly and as US Ambassador to the Commonwealth of The Bahamas. He also serves on the Board of Directors of Positive ID Corp., HealthWarehouse.com, Inc., and Viscount Systems, Inc.

J. Mitchell Lowe joined the board in March of 2015. Mitch was a co-founder of Netflix and the former president of Redbox. He is our first independent director and based on his diverse background and wide-ranging expertise, we expect that he will assist us with various aspects of our business, including strategy development and implementation, executive recruiting and corporate governance matters. He served as Vice President of Business Development and strategic alliances for Netflix from 1998 to 2003.

Manny Flores is our Board member and brings business and professional experience, including direct oversight of the development of the Illinois medical cannabis dispensary regulations. Manny also has worked closely with state regulators throughout the country to help shape policy on significant and emerging issues in complex regulated industries. Currently a partner in the Banks and Financial Institutions.

Practice Group at the Chicago office of law firm Arnstein & Lehr LLP, he was Acting Secretary at the Illinois Department of Financial and Professional Regulation. Manny was a prosecutor in the Cook County State’s Attorney’s Office. As part of his board role with Notis Global, he serves as Chairman of the Audit Committee, and a member of the Compensation and Governance & Nominating Committees.

The Past – Medbox, Inc.

Before I address the problems related to the old Medbox, I want to make it clear that the previous Medbox management team has been changed, and the new Notis Global management team has been put into place. The new team has implemented policies and procedures to move us beyond these past problems.

I am very aware of the outstanding issues and shareholder concerns regarding possible securities law violations, which arose under the Company’s prior management. In late 2014, the Company became a part of a federal and U.S. Securities and Exchange Commission (SEC) investigation where the Company and its auditors received subpoenas pertaining to improper financial reporting.

In November of 2014, after a review by an audit committee and outside financial advisors, the Company concluded that its consolidated financial statements for the year ended December 31, 2012, the year ended 2013 including the first, second and third quarters of 2013, and for the first, second and third quarters of 2014 should no longer be relied upon. The Company then promptly restated them to correct the errors and bring them into conformity with accounting principles generally accepted in the United States of America (GAAP) and SEC regulations.

As you may know, our Company has recently received a Wells Notice from the SEC. The Notice indicates a preliminary determination by the SEC staff to recommend that the Commission file an enforcement action against the Company in connection with misstatements by prior management in the Company’s financial statements for 2012, 2013 and the first three quarters of 2014. This Notice will require time and effort to resolve and we are cooperating with the SEC. We do not yet know the outcome; however, we are working diligently with our legal team to address any issues raised by the Commission. This is an important and serious matter and we do not treat it lightly.

While I cannot change the past, I and our entire team are fully committed to moving the Company forward toward higher revenue generation, and in pursuing positive EBITDA as a long-term goal.

The Present – Notis Global Today

Notis Global is guided by four strong principles – credibility, compliance, consistency and control. I’ll talk about the four C’s throughout this letter and it will be clear how they apply.

In early 2016, our executive management team working with our board determined that the past needed to be put behind us and it is now time to focus on the future. Here’s how we see it evolving.

First, we have been divesting ourselves of our direct retail distribution of legal THC containing cannabis products from our holdings in San Diego, California, Portland, Oregon and in Mount Vernon, Washington, including the underlying property in Washington, as we transition to a company focused on producing high quality hemp oil (CBD) products. Based on discussions with the government officials on the local, state and national level we have decided to transition from any activity with any products or services that would bring us into contact with THC, the psychotropic chemical in marijuana.

With an eye firmly focused on the future–and ultimately FDA approval of hemp and CBD Oil production and sales in the United States—we are focusing on controlling our supply chain. Notis Global will control its destiny by controlling our ecosystem from “seed to sale.” We intend to oversee and actively manage every phase of our operations from the seeds used to grow the mother cloning plants, through planting, cultivation, harvesting, processing, extraction, packaging, and sale.

Our “seeds to sale” strategy will result in some necessary changes to our existing business agreements. Following certain disputes with Whole Hemp (now known as Folium Biosciences), we have decided to end our relationship with Whole Hemp. In its place, the Company will directly or through contractors directed by the Company, will conduct the farming operations formerly performed through Whole Hemp.

Operational Developments – the Farm

Developing and executing a multiyear plan is no easy task, but with the right team we have been making excellent progress. One of our integral partners and contractors is Mark Marsh who along with his family have been successful local farmers on a commercial scale for multiple generations. Mark is responsible for overseeing the farming operations.

Our plan is to use our greenhouses for mother plants and cloning. We currently have built six greenhouses (36,000 square feet) with crops growing in three and ready to go into a fourth. We have been growing these “mother plants” which are then cloned and grown as genetically identical plants which are cultivated into an exceptional product. The cloned plants will grow very quickly in the Farm’s superior conditions.

Most significantly, we are expanding our planting from 10 up to 40 acres immediately and are planning to be farming on up to 200 acres in June. As you may know, our original plan was to farm 10 acres this year, then increase the acreage to 30 and 50 acres in the following year. We have accelerated those plans substantially and are executing them today. While we execute these plans we are increasing the vetting process of contractors to assure they are compliant with all applicable laws.. Additionally, we continue to work with the local municipalities and most especially the City of Pueblo, Colorado to take advantage of policies and programs that they offer.

For a brief video from March of 2016 showing the progress on the Pharm click here: https://www.youtube.com/watch?v=ouDXJHZHqJc

With our move to seed to sale control and quality assurance we are designing enhancements to the production and more significantly, the oil extraction process and moving that entire system in-house.

Re-branding

With the help and guidance of a widely respected branding agency, our new name, Notis Global, was researched, refined and established as our brand. The Notis Global brand name was selected for a specific reason: to instantly convey credibility in the burgeoning, worldwide multi-billion dollar hemp oil (CBD) industry.

Notis means ‘to make aware of, bring attention to, or to be deserving of special attention’ which our team agreed worked well for our mission, which is to bring attention to our Company and to establishing a leadership role in the health and hemp oil industry. The Global part of our new name reflects our goal to pursue a global strategy and to operate internationally as well as here at home. With our fresh new name and brand came a logo and a new ticker symbol, which as you know is NGBL and trades on the OTCQB.

Business Activities

We continue to have discussions with potential partners in Europe and elsewhere to assist us with best practices, newer more efficient and effective technology, product development and distribution opportunities.

We are striving to raise additional capital to repay more of our outstanding debt.

The Company’s executive management team and board bring a broad range of skills and experience relevant to the hemp oil industry. As we continue to grow, we plan to do so in a manner that best complies with all local, state, federal and international laws and regulations and follows best manufacturing practices, and sustainable organic farming.

The Future

The future of Notis Global is bright. We believe that medical marijuana and its benefits are no longer an ethical issue, but a relational issue. Everyone knows someone in pain, with epilepsy, cancer, or diagnosed with a disease who could benefit from the healthy use of cannabidiol based products to lessen the discomfort or reduce their pain. We believe that we will be a significant contributor helping deliver these products into the marketplace, where legalized, and that much human suffering could be alleviated.

The hemp oil business is a global industry which is changing rapidly and I feel that we have a tremendous opportunity, the right team and a solid plan for Notis Global. We can help define and elevate cannabinol production as an industry and provide international influence for good as a more products are accepted into the mainstream commerce. We as a team strongly believe in this industry and in this Company. As new legislation is approved, we are taking steps forward to serve the growing demand for CDB hemp oil products in this disruptive and emerging industry. Our board, our management team and I are working diligently and productively to develop trust in Notis Global, and to re-position the Company with new capital on better terms and to create sustainable revenue opportunities that will create value for the stakeholders in the Company.

I am honored to serve as this Company’s President and Chief Executive Officer. On behalf of our entire management team, our board of directors and myself, thank you for your continued belief in and support of Notis Global. 

About Notis Global

Based in Los Angeles, Notis Global is a pioneer in the burgeoning, multi-billion dollar hemp industry. The Company and its partners are working to grow confidence and generate revenues in the hemp oil industry. Through our key partnerships, Notis is a leading provider and distributor of cannabidiol (CBD). For more information on the Company, please visit http://NotisGlobal.com.

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “aim,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” “goal,” “strive,” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), and including not limited to Risk Factors relating reflected in the Company’s Annual Report on Form 10-K filed with the Commission on April 13, 2016. Thus, actual results could be materially different. We advise you review our Annual Report and the Risk Factors set forth therein. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Our audited financial statements for the year ended December 31, 2015, were prepared under the assumption that we would continue our operations as a going concern. Our independent registered public accounting firm has included a “going concern” explanatory paragraph in its report on our financial statements for the year ended December 31, 2015, indicating that we have sustained substantial losses from continuing operations and have used, rather than provided, cash in our continuing operations, and that these factors raise substantial doubt about our ability to continue as a going concern.

Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the near future and thereafter, and there are no assurances that such funding will be available at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Without additional funds from generation of revenues through execution of our business plan, debt or equity financings, sales of assets, or other transactions, we will exhaust our resources and will be unable to continue operations. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us. See Liquidity and Capital Resources under Item 7. Management’s Discussion and Analysis in our Annual Report on Form 10-K for further information regarding the Company’s efforts to secure liquidity and future cash flows. The Company has granted to an investor a lien against its equity interests in EWSD and its other assets as security for repayment of a note in the amount of approximately $225,000 and retains the right to pledge all or any part of its real or personal property to secure Company’s indebtedness in its sole discretion. If the Company is unable to meet the obligation that gave rise to this lien or to future liens on such stock and assets, it may default on such obligation or on future obligations and its lenders could foreclose upon, or cause the sale of, the Company’s ownership of EWSD.

SOURCE: Notis Global, Inc.

ReleaseID: 440439